A how-to guide for a precision medicine approach to the diagnosis and treatment of Alzheimer's disease
Article purposeThe clinical approach to Alzheimer's disease (AD) is challenging, particularly in high-functioning individuals. Accurate diagnosis is crucial, especially given the significant side effects, including brain hemorrhage, of newer monoclonal antibodies approved for treating earlier s...
Main Author: | Gayatri Devi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-08-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2023.1213968/full |
Similar Items
-
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
by: Gayatri Devi, et al.
Published: (2018-12-01) -
Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer’s Disease
by: Connie Yoon, et al.
Published: (2024-03-01) -
Impact of the biological definition of Alzheimer’s disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?
by: S. Gauthier, et al.
Published: (2018-05-01) -
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
by: Chad J. Swanson, et al.
Published: (2021-04-01) -
Beyond lecanemab: Examining Phase III potential in Alzheimer's therapeutics
by: Hitoshi Osaka, et al.
Published: (2024-03-01)